HC Wainwright Has Pessimistic Outlook of STOK Q2 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.68) per share for the quarter, down from their prior estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($1.41) EPS.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

A number of other research analysts have also commented on the stock. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday. Chardan Capital restated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.20.

Stoke Therapeutics Stock Performance

STOK opened at $9.63 on Friday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.58. The stock has a market capitalization of $525.77 million, a P/E ratio of -4.59 and a beta of 1.20. The business’s 50-day simple moving average is $8.12 and its 200-day simple moving average is $9.99.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Stoke Therapeutics by 29.2% in the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company’s stock valued at $220,000 after buying an additional 4,512 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after acquiring an additional 38,446 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth approximately $1,423,000. Bank of New York Mellon Corp increased its stake in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after purchasing an additional 1,330 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after purchasing an additional 2,787 shares during the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 over the last ninety days. 11.30% of the stock is currently owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.